The validated disease activity score for all ANCA-associated vasculitides. Fifty-six items across nine organ systems scored as new/worse (full points) or persistent (half points). A score of zero defines complete remission. Used as the primary endpoint in RAVE, RITUXVAS, MEPEX, and PEXIVAS trials.
Original Development
Mukhtyar C, Lee R, Brown D, et al.
Ann Rheum Dis, 2009
Scoring rule: Items present due to active vasculitis are scored as New/Worse (full points) or Persistent/Same (half points, rounded down). Only features attributable to active vasculitis should be scored. BVAS = 0 defines complete remission.
1
General
Scoring: For each feature, select whether it is new/worse (full score) or persistent/same (half the score, rounded down). Only include features due to active vasculitis.
Myalgia (max 1 pts)
Arthralgia or arthritis (max 1 pts)
Fever < 38.5 C (max 1 pts)
Fever > 38.5 C (max 2 pts)
Weight loss > 2 kg (max 2 pts)
2
Cutaneous
Scoring: For each feature, select whether it is new/worse (full score) or persistent/same (half the score, rounded down). Only include features due to active vasculitis.
Infarct (max 2 pts)
Purpura (max 2 pts)
Other skin vasculitis (max 2 pts)
3
Mucous membranes and eyes
Scoring: For each feature, select whether it is new/worse (full score) or persistent/same (half the score, rounded down). Only include features due to active vasculitis.
Conjunctivitis, episcleritis, keratitis, uveitis or retinal changes (max 2 pts)
Sudden visual loss (max 6 pts)
4
ENT
Scoring: For each feature, select whether it is new/worse (full score) or persistent/same (half the score, rounded down). Only include features due to active vasculitis.
Bloody nasal discharge, nasal crusts or ulcers (max 2 pts)
Paranasal sinus involvement (max 2 pts)
Subglottic involvement (max 6 pts)
Conductive hearing loss (max 2 pts)
Sensorineural hearing loss (max 3 pts)
5
Chest
Scoring: For each feature, select whether it is new/worse (full score) or persistent/same (half the score, rounded down). Only include features due to active vasculitis.
Wheeze (max 2 pts)
Nodules or cavities (max 2 pts)
Pleural effusion or pleuritis (max 2 pts)
Infiltrate (max 2 pts)
Endobronchial involvement (max 4 pts)
Massive haemoptysis or alveolar haemorrhage (max 4 pts)
Respiratory failure (max 6 pts)
6
Cardiovascular
Scoring: For each feature, select whether it is new/worse (full score) or persistent/same (half the score, rounded down). Only include features due to active vasculitis.
Loss of pulses (max 4 pts)
Valvular heart disease (max 4 pts)
Pericarditis (max 3 pts)
Ischaemic cardiac pain (max 4 pts)
Cardiomyopathy (max 6 pts)
Congestive cardiac failure (max 6 pts)
Stroke (max 6 pts)
Other CNS ischaemia (max 9 pts)
7
Abdominal
Scoring: For each feature, select whether it is new/worse (full score) or persistent/same (half the score, rounded down). Only include features due to active vasculitis.
Peritonitis (max 9 pts)
Bloody diarrhoea (max 9 pts)
Ischaemic abdominal pain (max 9 pts)
8
Renal
Scoring: For each feature, select whether it is new/worse (full score) or persistent/same (half the score, rounded down). Only include features due to active vasculitis.
Hypertension (max 4 pts)
Proteinuria > 1+ or > 0.2 g/24 hours (max 4 pts)
Haematuria > 1+ or > 5 RBCs/hpf (max 8 pts)
Creatinine 125-249 micromol/L (max 8 pts)
Creatinine 250-499 micromol/L (max 10 pts)
Creatinine >= 500 micromol/L or rise > 30% or creatinine doubling (max 12 pts)
9
Nervous system
Scoring: For each feature, select whether it is new/worse (full score) or persistent/same (half the score, rounded down). Only include features due to active vasculitis.
Headache (max 1 pts)
Meningitis (max 3 pts)
Organic confusion (max 3 pts)
Seizures (not hypertensive) (max 9 pts)
Stroke (max 9 pts)
Spinal cord lesion (max 9 pts)
Cranial nerve palsy (max 6 pts)
Sensory peripheral neuropathy (max 6 pts)
Motor mononeuritis multiplex (max 9 pts)
📊 Interpreting BVAS
BVAS
Status
Clinical Meaning
0
Complete Remission
No active vasculitis features. Required for RAVE/RITUXVAS remission definition.
1 to 5
Minor Activity
Low-level disease activity. May reflect persistent minor features rather than true relapse.
6 to 15
Moderate Activity
Significant active vasculitis requiring treatment.
Above 15
Severe Activity
Severe or life-threatening vasculitis. Urgent aggressive immunosuppression required.
BVAS = 0 with no glucocorticoids = true remission per most trial definitions. In RAVE and RITUXVAS, complete remission required BVAS = 0 and prednisolone dose below 10 mg/day. The VDI (Vasculitis Damage Index) should be used alongside BVAS to track irreversible damage accumulation.
💡 Pearls and Pitfalls
✓
BVAS v3 is the current standard - do not use BVAS/WG. BVAS version 3 (2009) is the validated standard for all AAV. BVAS/WG (Birmingham Vasculitis Activity Score for Wegener's Granulomatosis) was a predecessor specific to GPA. Most modern trials use BVAS v3. The persistent item half-scoring is specific to v3.
✓
Attribution is the key challenge. BVAS requires physician judgment to distinguish vasculitis activity from infection, drug toxicity, damage (fibrosis), and comorbidities. Particularly challenging areas: pulmonary infiltrates (vasculitis vs. infection), renal impairment (active nephritis vs. chronic damage), and ENT features (active disease vs. sequelae).
⚠
BVAS does not capture organ damage. Irreversible damage (fibrosis, structural changes, treatment toxicity) is captured by the VDI (Vasculitis Damage Index), not BVAS. A patient may have BVAS = 0 (remission) but significant VDI accumulation predicting poor prognosis.
🔮 Evidence
BVAS v3 was developed by Mukhtyar, Lee, Brown, and colleagues and published in Annals of the Rheumatic Diseases in 2009. It was designed to replace the original BVAS (Luqmani, 1994) and BVAS/WG with a single validated tool applicable across all ANCA-associated vasculitides. BVAS v3 was the primary activity endpoint in RAVE (rituximab vs. cyclophosphamide), RITUXVAS, MEPEX (methylprednisolone vs. plasma exchange), and PEXIVAS.
View References▾
1
Mukhtyar C, Lee R, Brown D, et al.Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68(12):1827-1832.
2
Stone JH, Merkel PA, Spiera R, et al.Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221-232. RAVE trial using BVAS as primary endpoint.
For clinical decision support only. BVAS requires physician expertise to correctly attribute features to active vasculitis. Use alongside VDI to comprehensively assess vasculitis disease burden.
BVAS = 0: No active vasculitis features. This is the definition of complete remission used in RAVE and RITUXVAS trials. Continue maintenance therapy and monitor closely.